C12Y 301/04017
3',5'-cyclic-nucleotide phosphodiesterase
Official title: 3',5'-Cyclic-nucleotide phosphodiesterase (3.1.4.17)
C12Y301/04017 (3',5'-cyclic-nucleotide phosphodiesterase) appears on 17 US grants and 35 published applications in this corpus.
Search patents in C12Y- Granted patents
- 17
- Published applications
- 35
- Assignees
- 29
- Inventors
- 94
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 1 | 1 |
| 2010 | 0 | 3 |
| 2011 | 0 | 0 |
| 2012 | 1 | 3 |
| 2013 | 0 | 0 |
| 2014 | 2 | 1 |
| 2015 | 1 | 2 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 2 | 0 |
| 2019 | 1 | 2 |
| 2020 | 0 | 1 |
| 2021 | 1 | 3 |
| 2022 | 0 | 6 |
| 2023 | 0 | 2 |
| 2024 | 2 | 2 |
| 2025 | 1 | 2 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Materials and methods for detecting and treating autoimmune movement disorders25 Aug 2026US 12,716,893 B2Mayo Foundation for Medical Education and Research
- Identification of PDE3 modulator responsive cancers10 Jun 2025US 12,325,880 B2The Broad Institute, Inc.
- Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors22 Oct 2024US 12,123,001 B2Regeneron Pharmaceuticals, Inc.
- PDE5A destabilizing domains6 Feb 2024US 11,891,634 B2The Board of Trustees of the Leland Stanford Junior University
- Treatment of synucleinopathies16 Feb 2021US 10,918,628 B2Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne)
- Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors12 Jun 2025US 2025/0188473 A1Regeneron Pharmaceuticals, Inc.
- Methods of lowering blood glucose and treating type 2 diabetes by activation of pde4d313 Mar 2025US 2025/0082781 A1The Salk Institute for Biological Studies
- Metabolic disorder-associated target gene irna compositions and methods of use thereof19 Sep 2024US 2024/0309370 A1Alnylam Pharmaceuticals, Inc.
- Pde5a destabilizing domains16 May 2024US 2024/0158770 A1The Board of Trustees of the Leland Stanford Junior University
- Peptide nucleic acid complex having endosomal escape capacity, and use thereof22 Jun 2023US 2023/0193275 A1Seasun Therapeutics
Most cited
By later US patents
- Human cyclic nucleotide PDEs46US 6,100,037 AIncyte Pharmaceuticals, Inc. · 2000
- 22025, a novel human cyclic nucleotide phosphodiesterase12US 6,146,876 AMillennium Pharmaceuticals, Inc. · 2000
- Neuronal pain pathway3US 8,252,754 B2The Trustees of Columbia University in the City of New York · 2012
- 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor1US 7,098,015 B2Millennium Pharmaceuticals, Inc. · 2006
- Phosphodiesterase 4D7 as marker for malignant, hormone-sensitive prostate cancer1US 8,778,621 B2Koninklijke Philips N. V. · 2014